Schaffhausen, Switzerland, 17 May, 2021 – Neobiomics AB and Ewopharma AG have entered an exclusive distribution agreement valid for the territory of Switzerland. The agreement includes marketing and sales of Neobiomics’ proprietary product ProPrems® and is in effect immediately.
Neobiomics AB is a Sweden-based company specialized in pediatric health care, connected with the Innovation Incubator at Karolinska Institutet Innovation AB. Ewopharma AG is a Swiss company focused on marketing of prescription and OTC drugs as well as Consumer Health products.
Dr. Stefan Johansson, CEO and Founder of Neobiomics AB, regards the agreement as another milestone for ProPrems®: “We at Neobiomics are very happy to work with Ewopharma. Their expertise and knowledge of the Swiss market will enable easy access to ProPrems® in Switzerland. It is great to collaborate with such an experienced team in this important territory.”
Dr. Friederike Skott, Country Manager Switzerland Ewopharma AG, comments: “ProPrems®, Neobiomics’ high-quality multi-strain probiotic product, represents a very good fit for our portfolio of orphan disease products. The neonatology community in Switzerland is requesting a high-grade food for special medical purposes such as ProPrems®. We are proud to respond to an unmet need for a very vulnerable group of patients with the introduction of ProPrems® and look forward to working with the passionate and knowledge-driven team at Neobiomics.”
Neobiomics AB and Ewopharma AG announce an exclusive collaboration for distribution of ProPrems® in Switzerland
